ArticleMolecular biotechnology2025
Effects of Lycium barbarum Polysaccharide on Digestive Function and Intestinal Barrier Dysfunction in Septic Mice by Regulating JNK Pathway.
Article in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic Effects of Plant Polysaccharides and Probiotics: A Novel Dietary Approach for Parkinson's Disease Intervention.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the protective effects of Lycium barbarum polysaccharide (LBP) on digestive function and intestinal barrier integrity in septic mice, and to explore its underlying mechanisms. A total of 70 healthy male BALB/C mice were randomly assigned into five groups: blank control group (BG, n = 12), control group (CG, n = 12), low-dose group (LDG, n = 12, 200 mg/kg), medium-dose group (MDG, n = 12, 400 mg/kg), and high-dose group (HDG, n = 12, 800 mg/kg). A sepsis model was established by cecal ligation and puncture, followed by treatment with different doses of LBP. Digestive function was assessed by measuring body weight, food intake, and stool consistency. Histopathological changes in the small intestine were observed via hematoxylin and eosin (H&E) staining, and the activation of the JNK signaling pathway was analyzed by Western blotting. One week after model establishment, a dose-dependent increase in body weight was observed in the LBP-treated mice (P < 0.05). The LBP treatment groups exhibited higher food intake and significantly lower stool wet weight compared to the CG (P < 0.05). Gastric emptying rate followed the order: BG > HDG > MDG > LDG > CG (P < 0.05). The intestinal propulsion rate was ranked from high to low as CG > LDG > MDG > HDG > BG, while intestinal absorption capacity was ranked from high to low as BG > HDG > MDG > LDG > CG (P < 0.05). The expression of RNA and protein associated with the JNK pathway showed the order: BG > HDG > MDG > LDG > CG, whereas the expression of MUC2 followed the opposite order (P < 0.05). LBP treatment significantly prolonged the survival time of the septic mice (P < 0.05). LBP significantly improves digestive function and intestinal barrier integrity in septic mice by modulating the inflammatory response and inhibiting JNK pathway activation.
Indexed as
Identifiers
39730853What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.